We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+42.01%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$6.4B
AUM Growth
+$1.32B
Cap. Flow
-$45.9M
Cap. Flow %
-0.72%
Top 10 Hldgs %
60.92%
Holding
71
New
5
Increased
8
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$208M
2
GPCR icon
Structure Therapeutics
GPCR
+$27.9M
3
MGNX icon
MacroGenics
MGNX
+$25.7M
4
URGN icon
UroGen Pharma
URGN
+$20.8M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$11.8M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$62.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$61M
3
CVAC
CureVac
CVAC
+$42.6M
4
SLNO
Soleno Therapeutics
SLNO
+$36.6M
5
VRDN icon
Viridian Therapeutics
VRDN
+$30.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTKB icon
26
Cytek Biosciences
CTKB
$636M
$62.1M 0.97%
6,809,404
– –
ABOS icon
27
Acumen Pharmaceuticals
ABOS
$209M
$57.3M 0.9%
14,932,063
– –
PEPG icon
28
PepGen
PEPG
$200M
$55.3M 0.86%
8,131,952
– –
APGE
29
DELISTED
Apogee Therapeutics
APGE
$55.3M 0.86%
1,977,901
– –
SPRY icon
30
ARS Pharmaceuticals
SPRY
$423M
$51.8M 0.81%
9,459,678
– –
NKTX icon
31
Nkarta
NKTX
$206M
$51.5M 0.8%
7,805,129
– –
VOR icon
32
Vor Biopharma
VOR
$1.32B
$51.2M 0.8%
1,137,444
– –
ITOS
33
DELISTED
iTeos Therapeutics
ITOS
$48.4M 0.76%
4,417,259
– –
MDGL icon
34
Madrigal Pharmaceuticals
MDGL
$12.1B
$47.3M 0.74%
204,500
– –
URGN icon
35
UroGen Pharma
URGN
$2.04B
$46.3M 0.72%
3,083,430
+1,599,733
+108% +$20.8M
MGNX icon
36
MacroGenics
MGNX
$257M
$39M 0.61%
4,053,077
+3,711,077
+1,085% +$25.7M
CLYM
37
Climb Bio
CLYM
$799M
$35.5M 0.55%
13,150,849
– –
TSHA icon
38
Taysha Gene Therapies
TSHA
$1.65B
$32.7M 0.51%
18,472,503
– –
GHRS icon
39
GH Research
GHRS
$1.89B
$32.4M 0.51%
5,587,333
– –
ELVN icon
40
Enliven Therapeutics
ELVN
$3.91B
$29.4M 0.46%
2,122,465
– –
CCCC icon
41
C4 Therapeutics
CCCC
$422M
$27.6M 0.43%
+4,878,000
New +$11.1M
MLYS icon
42
Mineralys Therapeutics
MLYS
$2.56B
$27.3M 0.43%
3,178,476
– –
HOWL icon
43
Werewolf Therapeutics
HOWL
$47.6M
$23.7M 0.37%
6,144,881
– –
ACRV icon
44
Acrivon Therapeutics
ACRV
$78.4M
$23.7M 0.37%
4,810,508
– –
PLRX icon
45
Pliant Therapeutics
PLRX
$69.4M
$23.2M 0.36%
1,281,000
-481,000
-27% -$7.31M
THRD
46
DELISTED
Third Harmonic Bio
THRD
$22.3M 0.35%
2,033,056
+1,071,193
+111% +$8.49M
RNAM
47
DELISTED
Avidity Biosciences
RNAM
$22.2M 0.35%
2,454,533
-3,962,465
-62% -$26.5M
SLDB icon
48
Solid Biosciences
SLDB
$897M
$21M 0.33%
3,426,286
– –
GPCR icon
49
Structure Therapeutics
GPCR
$2.78B
$19.8M 0.31%
+486,832
New +$27.9M
TNYA icon
50
Tenaya Therapeutics
TNYA
$150M
$17.8M 0.28%
5,507,347
-1,211,136
-18% -$2.61M
1
2
3

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, RA Capital Management held 71 positions worth $6.4B, up 26% from $5.08B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

RA Capital Management's Q4 2023 filing shows 5 new, 8 increased, 9 reduced and 9 closed positions. Its largest new stake was Structure Therapeutics: 486,832 shares worth $19.8M. The largest sale was Cogent Biosciences, an estimated $62.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • RA Capital Management's largest Q4 2023 buy was Structure Therapeutics: 486,832 shares worth $19.8M.
  • RA Capital Management added most to Immunogen Inc in Q4 2023, an estimated $208M increase.
  • RA Capital Management's biggest Q4 2023 reduction was Ascendis Pharma A/S, cutting an estimated $61M.
  • RA Capital Management fully exited Cogent Biosciences in Q4 2023, selling an estimated $62.6M.
  • RA Capital Management's ten largest holdings make up 61% of its $6.4B portfolio in Q4 2023.
  • RA Capital Management opened 5 new positions and closed 9 in Q4 2023.
  • RA Capital Management's portfolio value rose 26% quarter-over-quarter to $6.4B.

Based on RA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.